Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 251

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 251
---
period ended June 30, 2024 for APx was calculated using its unaudited statements of operations for the six -monthperiod ended June 30, 2024, added with its audited statements of operations for the year ended December 31, 2023 and deducting its unaudited statements of operations for the six -monthperiod ended June 30, 2023. (iii)Under GAAP, changes in fair value of SPAC Public Shares subject to redemption is recognized as a change in equity. Under IFRS, said change in fair value is recognized in the statement of operations. Adjustments to Unaudited Pro Forma Combined Statement of Operations for the twelve-month period ended June 30, 2024 and the six-month period ended December 31, 2024 The pro forma adjustments, included in the unaudited pro forma condensed combined statement of operations for the twelve months ended June 30, 2024 and the six -monthperiod ended December31, 2024, are as follows: (1)Preliminary estimated transaction costs to be incurred by APx and OmnigenicsAI amount to approximately $5.88 million and $4.49 million (including legal fees, Earlybird fees and other expenses), respectively (total amount of $10.37 million). Of the aforementioned APx transaction expenses, $2.12million were recognized in its historical statement of financial position as of December31, 2024 and the remaining $3.76million had not been recognized as of that date. Regarding OmnigenicsAI’ estimated transaction expenses, $0.99million was recognized in its historical combined financial statements as of December31, 2024 and the remaining $3.5million had not been recognized as of that date. Transaction costs to be incurred by APx not recognized in its historical financial statements as of December31, 2024 ($3.76 million as described before) were considered in the estimated expense recognized in the Unaudited Pro Forma Combined Statement of Operations for the twelve -monthperiod ended June30, 2024, in accordance with IFRS2, disclosed in Note (2) under “ Adjustments to Unaudited Pro Forma Combined Statement of Operations for the twelve -month period ended June 30, 2024 and for the six -month period ended December 31, 2024” and Note (4) under “ Adjustments to Unaudited Pro Forma Combined Statement of Financial Position as of